What is the significance of inclusion in the Stock Connect programs?

Inclusion in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs allows mainland Chinese investors to trade BeiGene's Hong Kong-listed shares, potentially increasing trading volume, liquidity, and broadening the company's investor base.

What is the importance of being added to the Hang Seng Composite Index (HSCI)?

Inclusion in the HSCI, a major Hong Kong stock market index, often leads to increased visibility and potential investment from index-tracking funds and institutional investors, which can positively impact stock performance.

What is the status of BRUKINSA® in Canada?

Health Canada has accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) for the treatment of Waldenström’s macroglobulinemia (WM) and has granted it priority review status, indicating a potentially expedited review process.

What is priority review status?

Priority review status typically means that a regulatory agency, in this case, Health Canada, will expedite the review process for the drug submission, potentially leading to a faster marketing approval decision.

ONC/BEIGF 8-K SEC Disclosure

Summary

This 8-K filing from BeOne Medicines Ltd. (ONC) reports two significant developments for the company in early September 2020. Firstly, its ordinary shares were admitted to the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective September 7, 2020. This inclusion is expected to enhance liquidity and potentially broaden the investor base by allowing mainland Chinese investors access to its Hong Kong-listed shares. Additionally, the company's shares were added to the Hang Seng Composite Index (HSCI), a widely followed benchmark in Hong Kong, which may lead to increased institutional interest and investment flows into the stock.

Key Highlights

1BeiGene's ordinary shares included in Shanghai-Hong Kong Stock Connect effective September 7, 2020.
2BeiGene's ordinary shares included in Shenzhen-Hong Kong Stock Connect effective September 7, 2020.
3BeiGene's ordinary shares added to the Hang Seng Composite Index (HSCI).
4Health Canada accepted New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for Waldenström’s macroglobulinemia (WM).
5BRUKINSA® (zanubrutinib) NDS granted priority review status by Health Canada.

BeOne Medicines Ltd. 8-K Report, Corporate Update (Sep 9, 2020)

Summary

Key Highlights

Frequently Asked Questions